Peter Lobo is a Nephrology physician affiliated with University of Virginia. OpenAlex indexes 112 publications with 4,077 citations (h-index 30).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Uva Hospital W
Hospital Drive, 3rd Floor
Charlottesville, VA 229080001
Telephone
434-924-2187Registry record last updated 20 Mar 2017.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
41.5%Vitamin D3 Analog34.2%Calcitriol100%Part D≥37 patientsCorticosteroid7.2%Prednisone100%Part D<11 patientsCardiovascular
39%Angiotensin receptor blocker (ARB)9.5%Losartan Potassium100%Part D≥11 patientsCalcium channel blocker9.2%Amlodipine Besylate100%Part D≥13 patients+ 3 more classes in this area
Anti-infectives
6.8%Short-acting sulfonamides6.8%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 1990–2021 per NIH RePORTER. The latest:
- CpG and B cells, pretreated ex-vivo with natural IgM, protect against renal IRI
University of Virginia
FY2021$363,375R01DK114366 - CpG and B cells, pretreated ex-vivo with natural IgM, protect against renal IRI
University of Virginia
FY2020$363,375R01DK114366 - CpG and B cells, pretreated ex-vivo with natural IgM, protect against renal IRI
University of Virginia
FY2019$363,375R01DK114366
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Role of Natural IgM Autoantibodies (IgM-NAA) and IgM Anti-Leukocyte Antibodies (IgM-ALA) in Regulating Inflammation
Current topics in microbiology and immunology
2017 - Role of Natural Autoantibodies and Natural IgM Anti-Leucocyte Autoantibodies in Health and Disease
Frontiers in Immunology
2016 - Interactions between MSCs and Immune Cells: Implications for Bone Healing
Journal of Immunology Research
2015 - Sphingosine 1-Phosphate Receptor 3–Deficient Dendritic Cells Modulate Splenic Responses to Ischemia-Reperfusion Injury
Journal of the American Society of Nephrology
2015
Similar KOLs
Other experts from the same institution or the same specialty.
Mark Deboer, MD
University of Virginia
Frederick Hayden, MD
University of Virginia
Charles Landen, MD
University of Virginia
Edward H. Oldfield
University of Virginia
Andrew Levey, MD
Tufts Medical Center
Bertram Kasiske, MD
Hennepin Healthcare
Garabed Eknoyan, MD
Baylor College of Medicine
Lawrence Hunsicker, MD
University of Iowa
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”